Phase II study of pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantation

Phase II study of pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantation - Pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantation

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004792

Enrollment

Registered

2011-01-01

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with low-level positive cytomegalovirus antigenemia after allogeneic hematopoietic stem cell transplantation

Interventions

valganciclovir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: After allogeneic hematopoietic stem cell transplantation Low-level positive cytomegalovirus antigenemia (C7-HRP >=2/50,000WBCs and <10/50,000WBCs) No cytomegalovirus-associated disease Patients who can take medicines perorally Performance status 0-2 No major organ complication

Exclusion criteria

Exclusion criteria: Negative cytomegalovirus antibodies of both of donors and recipients T-cell depleted or CD34-positive cell selected transplantation Gut GVHD (>=stage 2) HLA more than 2 locus disparity

Design outcomes

Primary

Measure	Time frame
Efficacy of low-dose valganciclovir for low-level positive cytomegalovirus antigenemia	—

Secondary

Measure	Time frame
Safety of low-dose valganciclovir Incidence of cytomegalovirus-associated disease	—

Countries

Japan

Contacts

Public ContactKatsuto Takenaka

Kyushu University Hospital Dept of Hematology/Oncology

takenaka@intmed1.med.kyushu-u.ac.jp092-642-5230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026